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Objectives To identify genetic associations with hip
osteoarthritis (HOA), we performed a meta-analysis of
genome-wide association studies (GWAS) of HOA.
Methods The GWAS meta-analysis included
approximately 2.5 million imputed HapMap single
nucleotide polymorphisms (SNPs). HOA cases and
controls defined radiographically and by total hip
replacement were selected from the Osteoporotic
Fractures in Men (MrOS) Study and the Study of
Osteoporotic Fractures (SOF) (654 cases and 4697
controls, combined). Replication of genome-wide
significant SNP associations ( p ≤5×10−8) was
examined in five studies (3243 cases and 6891
controls, combined). Functional studies were
performed using in vitro models of chondrogenesis
and osteogenesis.
Results The A allele of rs788748, located 65 kb
upstream of the IGFBP3 gene, was associated with
lower HOA odds at the genome-wide significance level
in the discovery stage (OR 0.71, p=2×10−8). The
association replicated in five studies (OR 0.92,
p=0.020), but the joint analysis of discovery and
replication results was not genome-wide significant
( p=1×10−6). In separate study populations, the
rs788748 A allele was also associated with lower
circulating IGFBP3 protein levels ( p=4×10−13),
suggesting that this SNP or a variant in linkage
disequilibrium could be an IGFBP3 regulatory variant.
Results from functional studies were consistent with
association results. Chondrocyte hypertrophy, a
deleterious event in OA pathogenesis, was largely
prevented upon IGFBP3 knockdown in chondrocytes.
Furthermore, IGFBP3 overexpression induced cartilage
catabolism and osteogenic differentiation.
Conclusions Results from GWAS and functional
studies provided suggestive links between IGFBP3 and
HOA.
INTRODUCTION
Hip osteoarthritis (HOA) is one of the most
common forms of arthritis, with nearly 10% of
individuals over the age of 70 having this condi-
tion.1 The degeneration of the hip joint that occurs
with OA is characterised by a loss of articular
cartilage, an increase in new bone formation at the
margins of the bones, and remodelling of the bone
that is adjacent to the joint.2 HOA is associated
with pain and disability and often requires total
joint replacement.3 Currently, there are no available
treatments that can alter the course of this disease.
Genetic and environmental factors contribute to
HOA pathogenesis, and the heritability of HOA in
women has been reported to be as high as 60%.4
A number of genome-wide significant (GWS;
p≤5×10−8) single nucleotide polymorphism (SNP)
associations with HOA and related traits have been
identified. Variants at the GDF5 locus and MCF2L
locus have been associated with OA of the hip and
knee.5–8 DOT1L SNPs have been associated with
cartilage thickness and HOA,9 10 and SNPs near
the gene NCOA3 have been associated with
HOA.11 A recent genome-wide association study
(GWAS) of OA that included 24 sub-phenotypes
identified five GWS associations.12
It has been previously noted that the heterogen-
eity of radiographic HOA classification could
hinder the identification of genetic risk factors.13
OA is typically defined using a summary grade
score, such as the Kellgren and Lawrence (K/L)
score14 or the Croft score,15 but for a given
summary grade score, the radiographic features can
vary between studies.13 In order to minimise
phenotype heterogeneity, we selected 654 HOA
cases and 4697 HOA controls from two studies,
the Osteoporotic Fractures in Men (MrOS) Study
and the Study of Osteoporotic Fractures (SOF), in
which the same radiographic scoring methods were
applied by a common set of radiograph readers,
and we performed a GWAS meta-analysis of HOA.
GWS SNP associations were examined for replica-
tion in 3243 cases and 6891 controls from five
case–control studies. To link HOA-associated SNPs
with a potential target gene, we examined whether
significantly associated SNPs near IGFBP3 were
associated with circulating IGFBP3 through a
look-up of results from a GWAS meta-analysis of
circulating IGFBP3.16 The biological role of the
candidate gene IGFBP3 was evaluated through
functional studies using model systems of chondro-
genesis and osteogenesis.
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METHODS
Study populations and case and control definitions
In the MrOS and SOF studies, HOA cases were defined using a
modified Croft grade score ≥2 on either hip or total hip
replacement (THR).2 HOA controls were those without THR
and meeting the following three criteria on both hips: Croft
grade ≤1, joint space narrowing ≤1 and osteophytes ≤1. GWS
SNP associations were examined for replication using case–
control status defined by K/L scores or THR in the Rotterdam
study (RS-I and RS-II) and Chingford study, and by THR in the
Genetics of Osteoarthritis and Lifestyle (GOAL) study and the
Nottingham Study. See online supplementary text S1 for details
regarding study descriptions and case–control definitions. All
studies were approved by their respective institutional review
boards and informed consent was obtained from all participants
involved.
Genotyping and statistical analysis
Genome-wide SNPs were genotyped in samples from the MrOS
and SOF studies using the Illumina HumanOmni1-Quad array.
Quality control procedures for SNPs and samples are described
in online supplementary table S1. Principal component analysis
was performed to detect evidence for population structure and
to generate principal components used to adjust for genetic
ancestry.17 Genotypes were imputed using the HapMap phase II
release 22 reference panel using MACH.18 SNP associations
were estimated using logistic regression models adjusted for the
effects of age, sex (if applicable), study site (if applicable) and
principal components. Genomic control was applied to results
from MrOS and SOF, and fixed-effect meta-analysis with
inverse variance weights was performed using METAL.19 The
two discovery studies and five replication studies were included
in the joint meta-analysis as individual studies. Details regarding
genotyping and statistical analysis in discovery and replication
studies are presented in online supplementary table S1 and text S1.
Cell culture experiments
Functional studies of chondrogenesis and osteogenesis were per-
formed using the ATDC5 and MC3T3 cell lines, respectively.
The ATDC5 cell line exhibits multi-stage chondrogenic
differentiation similar to the process that is observed during
chondrogenesis and endochondral bone formation.20 Human
articular chondrocytes, isolated from OA patients as previously
described,21 were also used in functional studies. Gene knock-
down was performed by stable transfection with plasmid overex-
pressing shmiRNA directed against IGFBP3. Further details are
presented in online supplementary text S1.
RESULTS
Characteristics of the study samples
Average age was significantly higher in MrOS participants
(100% male) than SOF participants (100% female). Age and
minimum joint space width differed by case–control status in
MrOS and SOF, but height and body mass index (BMI) did not
(see online supplementary table S2).
Locus associated with HOA
A GWAS of HOA was performed with 2 459 845 genotyped
and imputed SNPs that passed quality control. There was little
to no evidence of p value inflation in the individual studies
(MrOS λ=1.01, SOF λ=1.01) or the meta-analysis (λ=1.00)
(see online supplementary figures S1–S3). GWS SNPs were
located at a single locus on chromosome 7 (see online supple-
mentary figure S4). The two GWS SNPs, rs788748 and
rs879966, were directly genotyped in both cohorts, and were in
moderate linkage disequilibrium (LD) (HapMap CEU r2=0.54),
and the effect alleles were associated with decreased odds of
HOA (table 1 and figure 1). The nearest gene was IGFBP3
(figure 1). In conditional analysis, the HOA association p values
were not significant for rs788748 and rs879966 (p≥0.05), indi-
cating a strong degree of dependence.
Our discovery stage had sufficient power (≥0.8) at
α=5×10−8 to detect an OR of 0.68 for SNPs with a minor
allele frequency (MAF) of 0.5. As sufficient power was nearly
achieved to detect the observed rs788748 OR, the winner’s
curse22 adjusted23 rs788748 OR of 0.75 was similar to the
observed OR of 0.71.
Genetic variants in components of the growth hormone/
insulin-like growth factor (GH/IGF) axis, which includes
IGFBP3, have been associated with human height,24 and genetic
Table 1 SNP association results in discovery and replication studies
rs788748 rs879966
Chr 7: 45 992 706* Chr 7: 46 015 992*
A (0.49)† G (0.39)†
Cases/controls OR (95% CI) p Value OR (95% CI) p Value
MrOS 411/2512 0.68 (0.58 to 0.79) 7×10−7 0.67 (0.57 to 0.78) 8×10−7
SOF 243/2185 0.76 (0.63 to 0.92) 5×10−3 0.74 (0.61 to 0.91) 4×10−3
Meta-analysis 654/4697 0.71 (0.63 to 0.80) 2×10−8 0.70 (0.61 to 0.79) 1×10−8
Replication
GOAL 1291/783 0.85 (0.75 to 0.97) 0.01 ND ND
Nottingham 1258/758 1.01 (0.89 to 1.16) 0.83 ND ND
RS-I 462/3428 0.86 (0.74 to 0.99) 0.03 0.92 (0.79 to 1.06) 0.24
RS-II 149/1430 0.98 (0.75 to 1.28) 0.88 1.09 (0.83 to 1.44) 0.54
Chingford 83/492 1.11 (0.79 to 1.56) 0.54 1.00 (0.72 to 1.40) 0.99
Meta-analysis replication 3243/6891 0.92 (0.86 to 0.99) 0.02 0.96 (0.85 to 1.08) 0.48
*NCBI build 36 chromosome and position.
†Effect allele (effect allele frequency).
GOAL, Genetics of Osteoarthritis and Lifestyle Study; MrOS, Osteoporotic Fractures in Men Study; ND, not determined; RS, Rotterdam Study; SNP, single nucleotide polymorphism; SOF,
Study of Osteoporotic Fractures.
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associations are shared between OA and height.25 Rs788748
and rs879966 were in low LD (1000 Genomes phase 1 CEU
r2=0.09 and 0.16, respectively) with a functional IGFBP3 pro-
moter polymorphism (−202 A/C, rs2854744)26 associated with
GH-dependent growth,27 and adjustment for height or BMI had
a minimal effect on rs788748 and rs879966 HOA associations
(see online supplementary table S3), indicating that height is
unlikely to mediate the SNP associations.
The two GWS SNP associations were examined for replica-
tion in five HOA case–control studies (see online supplementary
tables S4 and S5). In the meta-analysis of replication results, the
rs788748 HOA association was significant and in the same dir-
ection as the discovery stage (p=0.020), with little evidence for
heterogeneity (Q test p=0.20, I2=36.67) (table 1, figure 2). The
rs879966 genotyping assay failed in the two largest replication
studies, GOAL and Nottingham, and not surprisingly, it was not
significantly associated with HOA among the replication studies
(table 1). In a joint meta-analysis of discovery and replication
stage results, the rs788748 OR (95% CI) was 0.86 (0.81 to
0.91) and the p value was 1×10−6.
Previously reported SNP associations with OA at rs11177/
rs6976 near GNL3/GLT8D1,12 rs10948172 near SUPT3H and
RUNX2,12 rs11842874 in MCF2L,8 rs12982744 in DOT1L,9 10
and rs6094710 near NCOA311 were significantly associated
(p≤0.05) with HOA in study-specific or meta-analysis results,
but the direction of effect did not replicate for rs11842874 or
rs6094710 (see online supplementary table S6).
Characterisation of associated SNPs
ENCODE project data indicated that histone modifications typ-
ically associated with enhancers (histone-3 lysine-4 mono-
methylation and histone-3 lysine-27 acetylation)28 were located
near rs788748 and rs879966. In addition, DNase I hypersensi-
tivity sites and transcription factor binding sites identified using
ChIP-Seq were located near rs788748 (see online supplementary
figure S5).
A GWAS meta-analysis of circulating IGFBP3 and IGF-I levels
reported an association region that spanned rs788748 and
rs879966, but the association estimates for these two SNPs were
not reported.16 A look-up of the associations for these SNPs
revealed that the rs788748 and rs879966 alleles associated with
lower odds of HOA were significantly associated with lower
Figure 1 Regional hip osteoarthritis (HOA) association plot of IGFBP3 locus. Association p values are plotted against genomic location. Negative
log base 10 of the association p value is shown on the left-hand y-axis. The HapMap-based recombination rate is shown on the right-hand y-axis
and is depicted using light blue peaks. Genomic location on chromosome 7 in megabases is shown on the x-axis. The dashed line marks the
genome-wide significance threshold. HapMap CEU linkage disequilibrium (r2) relative to the index single nucleotide polymorphism (SNP), rs788748,
is shown using filled colours according to the legend. RefSeq genes are shown in the bottom panel.
Figure 2 Forest plot of rs788748 hip osteoarthritis association. Point
sizes are proportional to the inverse variance weights, and 95% CIs are
shown. Within discovery and replication stages, studies are ordered by
the number of cases. GOAL, Genetics of Osteoarthritis and Lifestyle
Study; MrOS, Osteoporotic Fractures in Men Study; RS, Rotterdam
Study; SOF, Study of Osteoporotic Fractures.
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circulating IGFBP3 but not circulating IGF-I (R Kaplan, per-
sonal communication) (table 2). The two reported independent
SNPs most significantly associated with circulating IGFBP3
(rs11977526 and rs700752)16 were not significantly associated
with HOA (see online supplementary table S7). Based on
HapMap CEU genotypes, rs788748 was in low LD with
rs11977526 (r2=0.05), rs700752 (r2=0.04) and a potentially
causal SNP related to IGFBP3 levels, rs2854746 (r2=0.05).29
Functional studies of IGFBP3
The function of IGFBP3 was explored in the ATDC5 chondro-
genesis model system. Hypertrophic differentiation of chondro-
cytes, a process related to cartilage loss, is associated with
decreased expression of type II collagen and aggrecan, matrix
calcification, and increased expression of the Runx2 transcrip-
tion factor.30 Runx2, together with MEF2C, increases the
expression of type X collagen, matrix metalloproteinases
(MMPs) and Indian Hedgehog (Ihh).30
Efficient knockdown of IGFBP3 was achieved in ATDC5 cells
(figure 3A). By day 21, matrix calcification (Alizarin Red stain-
ing), sulfated proteoglycan synthesis (Alcian Blue and Safranin
O staining) and collagen content (Sirius red staining) were
reduced in IGFBP3− cells compared to controls (all p<0.05)
(see online supplementary figure S6), indicating that IGFBP3
knockdown impairs mineralisation and the early phase of
chondrogenesis.
IGFBP3 knockdown in ATDC5 cells resulted in a lack of
expression of type X collagen and lower expression levels of
Runx2 and Ihh, indicating that hypertrophy was largely pre-
vented (figure 3C, D, F). Expression of type II collagen was also
reduced, but to a lesser extent (figure 3B). WNT signalling is
known to activate Runx2 expression and stimulate hyper-
trophy.30 Consistent with prevention of hypertrophy, IGFBP3
knockdown resulted in lower levels of Tcf1, a marker of active
WNT signalling (figure 3E).
The effect of IGFBP3 overexpression was examined in articu-
lar cartilage isolated from patients who underwent knee replace-
ment for OA (figure 3G, H). Overexpression of IGFBP3 in
human articular cartilage pellets resulted in lower expression
levels of aggrecan (figure 3G) and increased expression of
MMP-13 (figure 3H), consistent with increased cartilage
catabolism.
HOA is a disease of both cartilage and bone, with a signifi-
cant component involving bone remodelling.31 The role of
IGFBP3 in osteogenic differentiation was examined using the
MC3T3-E1 cell-based model, a cell line that exhibits temporal
gene expression comparable to the in vivo differentiation
process.32 Knockdown experiments were not performed
because IGFBP3 is not expressed in the MC3T3-E1 cell line.33
IGFBP3 overexpression strongly enhanced extracellular matrix
mineralisation assayed by Alizarin Red staining and alkaline
phosphatase activity (see online supplementary figure S7a, b).
Expression levels of Osteocalcin and Osteopontin were 2.5- and
22.3-fold higher, respectively, in IGFBP3-overexpressing cells at
day 21 (see online supplementary figure S7c, d). At the first day
of induced IGFBP3 overexpression, before osteoblastogenesis
was induced, Osterix mRNA levels were already 50-fold higher,
and they remained 14-fold more expressed at day 21 (see online
supplementary figure S7e).
DISCUSSION
In this study, we identified a novel GWS HOA locus near the
gene IGFBP3. The genetic variant allele associated with lower
odds of HOAwas also associated with lower levels of circulating
IGFBP3, and experimental knockdown of IGFBP3 prevented
chondrocyte hypertrophic differentiation, a deleterious event in
OA pathogenesis that results in cartilage loss. Moreover,
IGFBP3 overexpression in articular cartilage from OA patients
increased expression of genes associated with cartilage catabol-
ism, and IGFBP3 overexpression in a cellular model of osteo-
genic differentiation resulted in an increase in matrix
mineralisation, consistent with an activation of osteoblastic dif-
ferentiation. Our results from GWAS and functional studies
indicate that IGFBP3 levels in cartilage are related to cartilage
maintenance and HOA.
Understanding molecular mechanisms underlying genetic
associations requires the identification of genes affected by asso-
ciated genetic variants.34 Our integration of a GWAS
meta-analysis of circulating IGFBP316 with our GWAS of HOA
revealed that the HOA-associated SNPs rs788748 and rs879966
were significantly associated with circulating IGFBP3, which
indicated that these SNPs or variants in LD could be regulatory
variants associated with IGFBP3 expression. Circulating IGFBP3
reflects IGFBP3 gene activity from multiple tissues, and asso-
ciated SNPs could be regulatory variants associated with
IGFBP3 expression in at least one tissue, which is then reflected
in circulating protein levels. These results cannot be used to
determine the tissue in which associated variants might regulate
IGFBP3, but the direction of effect for SNP alleles can be
inferred, namely, that the rs788748 A allele associated with
lower odds of HOA is also associated with lower levels of
IGFBP3 expression in at least one tissue. It is also important to
note that even though the SNPs near IGFBP3 previously
reported to be the most significantly associated with circulating
IGFBP316 are not significantly associated with HOA, these SNPs
explain a small percentage of the variance in IGFBP3 levels,
thus preventing meaningful interpretation of the relationship
between circulating IGFBP3 and HOA.
IGFBP3 is one of six insulin-like growth factor binding pro-
teins (IGFBPs) in humans.35 IGFBPs modulate IGF signalling by
Table 2 SNP association with circulating IGFBP3
IGFBP3 IGF-I
SNP EA (freq) p ValueGC Effect direction* I
2 p ValueGC Effect direction* I
2
rs788748 A (0.49) 6×10−13 −−−− 61.3 0.82 −− +− 0.0
rs879966 G (0.40) 4×10−5 −−−− 56.2 0.80 − ++− 0.0
rs788748 was genotyped in CHS, KORA and SHIP and imputed in FHS (imputation accuracy=1.0). rs879966 was genotyped in CHS and imputed in FHS, KORA and SHIP (imputation
accuracy=0.98, 0.99 and 0.99, respectively).
*Study order: KORA, FHS, SHIP and CHS.
EA, effect allele; SNP, single nucleotide polymorphism.
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binding to the two ligands (IGF-I and IGF-II) that primarily
signal through the type I IGF-I receptor (IGF-IR).35 In articular
cartilage from individuals without OA, IGF-I activates anabolic
processes and inhibits catabolism of cartilage.36–38 In OA cartil-
age, IGF-I’s anabolic activity is greatly diminished, despite the
presence of its receptor (IGF-IR).39 40 Higher levels of IGFBPs,
in particular IGFBP3, have been observed in OA cartilage,
leading to the notion that IGFBPs could decrease IGF-I’s bio-
availability and could at least be partially responsible for the
reduced responsiveness of OA cartilage to IGF-I.40–45
Consistent with this notion, an IGFBP-insensitive IGF-I
analogue exhibited a stronger anabolic effect on cartilage than
IGF-I alone,42 and a small molecule that inhibits the binding of
IGFBPs to IGF-I restored the anabolic effect of IGF-I on OA
chondrocytes.46 Our experimental results also suggest that
lower levels of IGFBP3 could promote cartilage maintenance.
Further studies are needed to determine whether the HOA asso-
ciation with rs788748 is mediated through a potential alteration
in the role of IGFBP3 in cartilage homeostasis during develop-
mental growth to determine joint morphology or perhaps
through a subtle impact on IGFBP3 throughout life to affect the
threshold for developing HOA. Furthermore, whether IGFBP3’s
Figure 3 Impact of IGFBP3 knockdown and overexpression on markers of cartilage homeostasis. ATDC5 cells stably transfected with a transgene
expressing siRNA directed against IGFBP3 are marked in red, and control cells in blue (A–F). IGFBP3 overexpression (grey bars) and control cells
(white bars) in articular cartilage (G and H). Gene expression levels quantified by RT-PCR were IGFBP3 (A), type II collagen/Col2A1 (B), type X
collagen/Col10A1 (C), Runx2 (D), Tcf1 (E), Ihh (F), aggrecan (G) and MMP13 (H). *p≤ 0.05 difference with day 1 levels. #p≤ 0.05 difference with
control at each day.
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effect on cartilage homeostasis depends on IGF-I will need to be
explored in future studies, as IGFBP3 possesses a nuclear local-
isation sequence, it has been found to localise to the nucleus in
cartilage, and it has been proposed to have IGF-independent
effects in other biological processes.35 47
The nearly complete elimination of IGFBP3 expression in our
knockdown experiments had strong effects on the prevention of
chondrocyte hypertrophy, but subtle effects on cartilage main-
tenance were also observed, arguing for a minimum required
level of IGFBP3. The HOA-associated variants rs788748 and
rs879966 were associated with a reduction, but not elimination,
of circulating IGFBP3. We also observed that chondrocyte
hypertrophy was stimulated by overexpression of IGFBP3 in OA
cartilage, which is already in a diseased state, leaving it
unknown whether this same effect would be observed in
healthy cartilage. With this caveat in mind, higher levels of
IGFBP3 could contribute to cartilage loss in diseased cartilage.
Taken together, our cell-based experiments argue for a certain
range of IGFBP3 in cartilage that supports healthy cartilage
homeostasis. In order for IGFBP3-targeted HOA treatments to
potentially be effective, this proposed healthy IGFBP3 range
will need to be carefully characterised. Furthermore,
IGFBP3-targeted therapies must consider the potential impacts
on cancer and other IGFBP3-associated diseases.35
A number of factors that regulate IGFBP3 expression have
been identified, but IGFBP3 transcriptional enhancers that func-
tion in chondrocytes are not well characterised.35 HMGA1
binds to several sites 2 kb upstream of the IGFBP3 promoter
and is required for IGFBP3 expression in chondrocytes,48 but
DNA near rs788748 and rs879966 has not been experimentally
tested for enhancer activity. HMGA1 binding data was not
included in the ENCODE project, but there is evidence that C/
EBPβ, HMGA1’s binding partner, binds DNA near rs788748
(see online supplementary figure S5). Functional studies of this
genomic region could help to elucidate the dynamic role
IGFBP3 plays in OA development.
Despite a directionally consistent and significant association
in the replication studies, the joint analysis p value (combined
discovery and replication) was less significant than the discovery
stage p value, which is not surprising given that the replication
stage sample size was larger and the replication stage effect size
was closer to the null, indicating a possible winner’s curse
effect22 even though a correction for this effect had little impact
on the discovery stage OR.23 While joint analysis provides
greater power in two-stage designs than replication analysis to
identify GWS associations, even greater power is achieved in
one-stage designs where genome-wide SNPs are genotyped in all
samples.49 We performed a one-stage design in the MrOS and
SOF cohorts to identify GWS SNP associations, followed by a
standard replication analysis of the two GWS associations in
independent studies. As genome-wide SNPs were tested in the
discovery stage, the significance threshold accounting for the
multiple testing burden should only be applied to discovery
stage results. Furthermore, given our allocation of studies in dis-
covery and replication, a replication stage two-tailed p value of
1×10−3 is required to achieve genome-wide significance in a
joint analysis (see online supplementary text S1), a threshold
that exceeds typical significance thresholds for replication.
Moreover, the practice of combining discovery and replication
stage results to achieve genome-wide significance has been
noted to present multiple testing problems.50
In summary, our results from GWAS and functional studies
support the role of IGFBP3 in HOA. Further work is needed to
determine whether IGFBP3’s effect on cartilage homeostasis
requires its interaction with IGF-I. If the IGFBP3 and IGF-I
interaction plays a role in HOA, consideration of this interaction
could enhance HOA therapies that target the anabolic effect of
IGF-I.
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